As microglia become more central to Alzheimer’s research, researchers are seeking better model systems to study their in vivo behavior. In culture, the cells rapidly alter their gene expression, and mouse microglia respond differently to disease than do their human counterparts. Chimeric mice may provide a solution. At the AD/PD meeting held March 27–31 in Lisbon, Portugal, two groups reported that human microglia transferred to mouse brain appeared to maintain their human identity (Apr 2019 conference news).
- Human microglia retain human gene expression profiles in mouse brain.
- They monitor their environment and activate in response to injury.
- They respond differently to amyloid than do mouse microglia.
Now, one of these groups has published their findings. In the July 30 Neuron, researchers led by Mathew Blurton-Jones at the University of California, Irvine, detail their chimeric mouse model, reporting that the transplanted microglia assume transcription states similar to those in human brain, surveil their surroundings, and respond appropriately to injuries and disease. In a mouse model of amyloidosis, human microglia had a distinct genetic response compared to mouse microglia. Researchers from Bart De Strooper’s lab at KU Leuven, Belgium, had reported very similar findings at ADPD. Their paper, currently under peer review, was posted to BioRχiv last February (Mancuso et al., 2019).
Other researchers expressed enthusiasm. “The work by Hasselmann et al. offers a powerful tool to better investigate human microglia during brain disease,” Marco Colonna and Simone Brioschi at Washington University in St. Louis wrote to Alzforum (full comment below). Oleg Butovsky at Brigham and Women’s Hospital, Boston, said this is the best approach to date for studying human microglia in vivo. “This is next-level, state-of-the-art work,” Butovsky said.
To create the chimeric mouse, joint first authors Jonathan Hasselmann and Morgan Coburn transplanted fluorescently labeled hematopoietic progenitor cells derived from human iPSCs into the cortices and lateral ventricles of newborn transgenic MITRG mice. These mice express a humanized form of the microglial growth factor CSF1, which is essential for microglial maintenance, and lack two immune factors required for rejection of foreign cells. Two months later, the human cells had differentiated into macrophages and microglia. Near the injection sites, about 80 percent of microglia had a human, rather than mouse, pedigree. The authors found that the gene expression profiles of these xenotransplanted microglia closely matched those of human microglia the authors isolated from brain surgery samples, as well as a previously studied ex vivo microglia (Gosselin et al., 2017). The profiles differed from those of cultured human microglia, suggesting the transplanted cells better model in vivo microglial phenotypes.
The human cells appeared to behave normally in the mice. Through a cranial window, the authors observed the cells extending and retracting processes as they surveyed their environment. In response to an acute brain injury produced by a laser, nearby human microglia extended processes into the damaged region. After repeated mild head trauma, they moved into the damaged tissue and cleaned up neuronal debris. When mice were peripherally injected with lipopolysaccharide to stimulate an inflammatory response, the xenotransplanted cells dialed down homeostatic genes and turned up genes involved in phagocytosis and cytokine recognition. Notably, the response to LPS in vivo was distinct from that of cultured human microglia exposed to LPS, with almost no gene expression overlap.
To find out how human microglia would respond to amyloid, the authors crossed 5xFAD and MITRG mice, then transplanted human hematopoietic progenitor cells into the pups. At nine months of age, human microglia crowded around amyloid plaques. The cells had a rounded shape, and expressed numerous markers characteristic of disease-associated microglia (DAM), such as ApoE, TREM2, CD9, CD11C, and MERTK (Jun 2017 news). However, transcriptomic analysis revealed large differences between the DAM response in transplanted human and mouse microglia. Ninety percent of the changes in human microglia did not occur in the mouse cells; these comprised upregulation of 342 and downregulation of 336 genes. The set included AD risk genes such as MS4A6A, ABCG2, and CD33. The findings dovetail with previous research showing mouse and human microglia respond differently to amyloid (Feb 2018 news). The authors chose two of the human upregulated genes, HLA-DRB1 and LGALS3, and confirmed that both are highly expressed in microglia around amyloid plaques in human brain, suggesting the findings reflect what happens in AD.
This chimeric system could be used to study how AD mutations affect microglial responses, Blurton-Jones noted. As a proof of concept, the authors transplanted human microglia expressing the TREM2 R47H mutation into 5X-MITRG mice. The mutant cells poorly migrated to plaques, which is in keeping with findings from mouse models and human postmortem brain (see image above). The authors are examining the effects of other AD risk genes. Blurton-Jones noted that the model could also be used to study polygenic effects, by comparing microglial lines generated from people with high versus low cumulative genetic risk of AD.—Madolyn Bowman Rogers
- Chimeric Mice: Can They Model Human Microglial Responses?
- Hot DAM: Specific Microglia Engulf Plaques
- Microglial Transcriptome Hints at Shortcomings of AD Model
Research Models Citations
- Gosselin D, Skola D, Coufal NG, Holtman IR, Schlachetzki JC, Sajti E, Jaeger BN, O'Connor C, Fitzpatrick C, Pasillas MP, Pena M, Adair A, Gonda DD, Levy ML, Ransohoff RM, Gage FH, Glass CK. An environment-dependent transcriptional network specifies human microglia identity. Science. 2017 Jun 23;356(6344) Epub 2017 May 25 PubMed.
- Hasselmann J, Coburn MA, England W, Figueroa Velez DX, Shabestari SK, Tu CH, McQuade A, Kolahdouzan M, Echeverria K, Claes C, Nakayama T, Azevedo R, Coufal NG, Han CZ, Cummings BJ, Davtyan H, Glass CK, Healy LM, Gandhi SP, Spitale RC, Blurton-Jones M. Development of a chimeric model to study and manipulate human microglia in vivo. Neuron. 2019 Jul 30